C Shapira - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

C Shapira

Showing results (91-100 of 93) with videos related to

Pageof 10

Sort By:

You have reached the last page of results.This site can display upto 93 results.

Iscience|May 3, 2021

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 miceTal Noy-Porat, Adva Mechaly, Yinon Levy, et al.

Cell Reports|August 31, 2021

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsEfi Makdasi, Anat Zvi, Ron Alcalay, et al.

Nature Communications|December 17, 2020

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challengeYfat Yahalom-Ronen, Hadas Tamir, Sharon Melamed, et al.

Pageof 10

Search research articles

Showing results (91-100 of 93) with videos related to

Sort By:

Pageof 10

You have reached the last page of results.This site can display upto 93 results.

Iscience|May 3, 2021

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 miceTal Noy-Porat, Adva Mechaly, Yinon Levy, et al.

Cell Reports|August 31, 2021

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variantsEfi Makdasi, Anat Zvi, Ron Alcalay, et al.

Nature Communications|December 17, 2020

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challengeYfat Yahalom-Ronen, Hadas Tamir, Sharon Melamed, et al.

Pageof 10